Maxalt

Rizatriptan, the active ingredient in Maxalt, is a triptan (selective 5‑HT1B/1D receptor agonist) presented as a tablet for oral use. It is indicated for the acute treatment of migraine attacks, with or without aura, in adult patients.

GNH USA supplies Maxalt as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for regulated markets. Its global distribution network ensures timely delivery and compliance with local regulatory requirements.

Maxalt, a triptan medication, is used to treat migraine-related conditions by targeting serotonergic pathways. - Migraine attacks: provides rapid relief of headache pain and associated symptoms. - Migraine with aura: reduces visual and sensory disturbances accompanying the attack. - Acute migraine: aborts the progression of an attack when taken early in the episode.

Rizatriptan may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Nausea: mild to moderate feeling of stomach upset. - Dizziness: transient light‑headedness or vertigo. - Fatigue: unusual tiredness or weakness. - Dry mouth: reduced salivation leading to throat discomfort.

Serious or Rare Side Effects: - Chest pain or tightness: possible cardiac ischemia requiring immediate evaluation. - Serotonin syndrome: agitation, hyperthermia, sweating, and muscle rigidity when combined with other serotonergic agents. - Severe allergic reaction: rash, itching, swelling, or difficulty breathing indicating anaphylaxis.

Before prescribing Maxalt, clinicians should consider several precautionary measures to ensure patient safety. - Cardiovascular assessment: evaluate history of coronary artery disease, hypertension, or stroke before use. - Concomitant serotonergic drugs: avoid co‑administration with SSRIs, SNRIs, or MAO inhibitors due to serotonin syndrome risk. - Pregnancy and lactation: use only if potential benefit outweighs potential risk, as safety data are limited. - Age considerations: exercise caution in elderly patients who may have increased sensitivity to vasoconstrictive effects. - Drug interactions: review all current medications for potential interactions listed in the product information. - Store at ambient temperature: keep tablets below 25 °C in the original packaging, protected from moisture and direct sunlight.

Rizatriptan can interact with other medicines, affecting its efficacy or safety profile.

Major Interactions (Avoid): - MAO inhibitors: risk of severe hypertension and serotonin syndrome. - Other triptans or ergot alkaloids: additive vasoconstriction may precipitate cardiovascular events. - Strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): increase rizatriptan plasma levels, heightening adverse effect risk.

Moderate Interactions (Monitor Closely): - SSRIs, SNRIs, or tricyclic antidepressants: monitor for signs of serotonin syndrome. - Antihypertensive agents: possible reduction in blood pressure control. - Oral contraceptives: may slightly increase risk of cardiovascular side effects.